Clinical Trials - MarketOpen Australia

October 16, 2025 Off

Argenica Therapeutics (ASX:AGN) delivers promising functional recovery trends in ARG-007 Phase 2 stroke trial

Dr Liz Dallimore, says the company’s latest Phase 2 trial results for ARG-007 demonstrate encouraging trends in patient recovery and mark an important step toward confirming the therapy’s clinical potential.

December 18, 2024 Off

Psilocin’s next target: Tryptamine Therapeutics (ASX:TYP) takes aim at IBS

By MarketOpen

Tryptamine Therapeutics (ASX:TYP) delivers promising interim results from its Phase 2a trial, with 75% of IBS patients reporting reduced abdominal pain and anxiety, marking a significant step for TRP-8803’s clinical pathway.

Tag: Clinical Trials

Argenica Therapeutics (ASX:AGN) delivers promising functional recovery trends in ARG-007 Phase 2 stroke trial

Psilocin’s next target: Tryptamine Therapeutics (ASX:TYP) takes aim at IBS

Contact info

Important links

Follow us

Argenica Therapeutics (ASX:AGN) delivers promising functional recovery trends in ARG-007 Phase 2 stroke trial

Psilocin’s next target: Tryptamine Therapeutics (ASX:TYP) takes aim at IBS

Subscribe